Literature DB >> 7200828

Cytotoxic effects and biological activity of 2-aza-8-germanspiro[4,5]-decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride (NSC 192965; spirogermanium) in vitro.

B T Hill, S A Whatley, A S Bellamy, L Y Jenkins, R D Whelan.   

Abstract

Lethal and other biological effects of 2-aza-8-germanspiro[4,5]decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride (NSC 192965; spirogermanium), representing a new chemical class of compound exhibiting antitumor activity, have been studied in vitro. Survival curves for NIL 8 hamster cells were exponential with greater kill occurring with increasing drug concentrations and longer exposure times. Cytotoxicity was temperature dependent. "Quiescent" cultures were significantly less sensitive to spirogermanium than were logarithmically growing cells. These lethal effects showed no phase specificity. There was no evidence of progression delay through the cycle following spirogermanium treatment. When spirogermanium was tested against a range of human cell lines, the consistency of the values for the drug concentration required to reduce survival by 50% on the exponential part of the survival curve, derived from colony-forming assays, was most marked. The survival curves, characterized by an initial shoulder, were steep and exponential with measurements possible over only a narrow concentration range since complete cell lysis occurred at levels causing a greater than 2-log kill. Cell membrane damage by spirogermanium, as judged by dye exclusion, was progressive with time and increasing drug concentrations. Protein synthesis proved most susceptible to the drug. Spirogermanium concentrations cytotoxic to tumor cells were also toxic to cultured rat neurons, confirming the clinical neurological toxicity encountered. The precise mode of action of spirogermanium remains to be established, and these data further illustrate its apparent lack of specificity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7200828

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

Review 1.  Nephrotoxicity and neurotoxicity in humans from organogermanium compounds and germanium dioxide.

Authors:  A G Schauss
Journal:  Biol Trace Elem Res       Date:  1991-06       Impact factor: 3.738

2.  Spirogermanium--a novel antitumour agent expressing a lack of cross-resistance in vitro with a range of 'standard' antitumour drugs.

Authors:  B T Hill; R D Whelan
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

3.  Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro.

Authors:  B T Hill; L Y Dennis; X T Li; R D Whelan
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Phase I study of oral spirogermanium.

Authors:  J Harvey; M McFadden; F P Smith; L Joubert; P S Schein
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

5.  Spirogermanium: a new investigational drug of novel structure and lack of bone marrow toxicity.

Authors:  M Slavik; O Blanc; J Davis
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

6.  Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.

Authors:  B T Hill; R D Whelan; S A Shellard; S McClean; L K Hosking
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

7.  Identification of synergistic combinations of spirogermanium with 5-fluorouracil or cisplatin using a range of human tumour cell lines in vitro.

Authors:  B T Hill; A S Bellamy; S Metcalfe; P J Hepburn; J R Masters; R D Whelan
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

8.  Comparative effectiveness of mitoxantrone and doxorubicin in overcoming experimentally induced drug resistance in murine and human tumour cell lines in vitro.

Authors:  B T Hill; L K Hosking; S A Shellard; R D Whelan
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

9.  Phase II study of spirogermanium in patients with advanced colorectal carcinoma.

Authors:  J A Ajani; J S Faintuch; R K McClure; B Levin; B M Boman; I H Krakoff
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

10.  Synthesis and evaluation of novel organogermanium sesquioxides as antitumor agents.

Authors:  Chun Li Zhang; Tai Hua Li; Shuang Huan Niu; Rong Fu Wang; Zhan Li Fu; Feng Qin Guo; Ming Yang
Journal:  Bioinorg Chem Appl       Date:  2009-06-02       Impact factor: 7.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.